Armata Pharmaceuticals Stock Alpha and Beta Analysis
| ARMP Stock | USD 6.24 0.12 1.89% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Armata Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Armata Pharmaceuticals over a specified time horizon. Remember, high Armata Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Armata Pharmaceuticals' market risk premium analysis include:
Beta (1.65) | Alpha 1.96 | Risk 14.68 | Sharpe Ratio 0.13 | Expected Return 1.89 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Armata Pharmaceuticals Backtesting, Armata Pharmaceuticals Valuation, Armata Pharmaceuticals Correlation, Armata Pharmaceuticals Hype Analysis, Armata Pharmaceuticals Volatility, Armata Pharmaceuticals History and analyze Armata Pharmaceuticals Performance. Armata Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Armata Pharmaceuticals market risk premium is the additional return an investor will receive from holding Armata Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Armata Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Armata Pharmaceuticals' performance over market.| α | 1.96 | β | -1.65 |
Armata Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Armata Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Armata Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Armata Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Armata Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Armata Pharmaceuticals shares will generate the highest return on investment. By understating and applying Armata Pharmaceuticals stock market price indicators, traders can identify Armata Pharmaceuticals position entry and exit signals to maximize returns.
Armata Pharmaceuticals Return and Market Media
The median price of Armata Pharmaceuticals for the period between Thu, Oct 2, 2025 and Wed, Dec 31, 2025 is 5.72 with a coefficient of variation of 28.01. The daily time series for the period is distributed with a sample standard deviation of 1.49, arithmetic mean of 5.31, and mean deviation of 1.27. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Schlesinger Sarah J. of 28000 shares of Armata Pharmaceuticals at 4.29 subject to Rule 16b-3 | 10/08/2025 |
2 | Will Armata Pharmaceuticals Inc. stock deliver consistent dividends - Trade Risk Report Risk Controlled Daily Plans - newser.com | 10/14/2025 |
3 | How Armata Pharmaceuticals Inc. stock performs during market turbulence - Market Risk Report Free High Accuracy Swing Entry Alerts - newser.com | 11/06/2025 |
4 | Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California | 11/10/2025 |
5 | Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update | 11/12/2025 |
6 | Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 1000am EST | 11/18/2025 |
7 | Comparing Armata Pharmaceuticals Inc. in custom built stock radars - CEO Change AI Forecasted EntryExit Points - newser.com | 11/21/2025 |
8 | Armata Pharmaceuticals Enters Capital Sales Agreement - TipRanks | 12/01/2025 |
9 | Is Armata Pharmaceuticals Inc. stock testing key support - July 2025 Pullbacks Verified Momentum Stock Watchlist - Newser | 12/05/2025 |
About Armata Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Armata or other stocks. Alpha measures the amount that position in Armata Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0166 | 0.0175 | Price To Sales Ratio | 12.93 | 12.28 |
Armata Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Armata Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Armata Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Armata Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Armata Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Armata Pharmaceuticals' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Armata Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.